Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Prevention and Treatment of Radiation Injury in Chest Radiotherapy
ChiCTR2400088714Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bronchial carcinoma, esophageal cancer, thymic malignancies (TET) and 3 more comparing Thalidomide arm with Placebo arm (2 arms). Primary endpoint: Incidence of radiation pneumonitis (all grades) in two groups. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
bronchial carcinomaesophageal cancerthymic malignancies (TET)radiation pneumonitis (RP)radiation esophagitis
Beyond the preview
Go deeper on ChiCTR2400088714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088714.